aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

aTyr Pharma recently revealed their financial results for the second quarter of 2026. The company disclosed plans to prioritize their Efzofitimod program for Interstitial Lung Disease (ILD), alongside a corporate restructuring effort. This decision aims to allocate resources effectively towards the Efzofitimod program. The restructuring will involve workforce adjustments, budget reallocations, and strategic initiatives to drive the ILD program forward. The company aims to enhance efficiency and streamline operations to focus on the development of Efzofitimod for ILD.